France’s medicines regulator has imposed significant fines on two major pharmaceutical companies for allegedly running misleading advertisements for their weight loss drugs.
The National Agency for Medicines and Health Products Safety (ANSM) fined Novo Nordisk approximately $2 million for advertisements promoting its medications Wegovy and Saxenda. The regulator deemed the ads misleading, raising concerns about their accuracy and compliance with advertising standards.
In a separate action, the ANSM also fined Eli Lilly roughly $127,000 for advertisements related to its obesity treatment Mounjaro. The regulator stated that the ads amounted to indirect promotion of a prescription-only medicine, violating regulatory guidelines.
The penalties reflect increasing regulatory scrutiny over the promotion of weight loss drugs as the market for these medications continues to expand rapidly. Two years ago, the ANSM issued a bulletin highlighting the risks associated with these drugs, particularly the dangers of inappropriate use.
Related articles
Optimal Sleep Duration May Slow Biological Aging, Study Finds
Recent research has found an association between sleep duration and biological aging. Image Credit: ArtistGNDphotography/Getty Images A recent study f...
Marty Makary's FDA Resignation Highlights Agency Turmoil Amid Leadership Shifts
On Tuesday, Food and Drug Administration Commissioner Marty Makary resigned from his position, leaving a vacancy at the top of the agency to match the...
GLP-1 Drugs Linked to Better Breast Cancer Outcomes in Obesity and Diabetes Patients
A recent study shows that GLP-1 drugs may help improve survival rates in people with breast cancer, obesity, and diabetes. Image Credit: Tatsiana Volk...
UK Political Shake-Up Could Reshape Global Drug Pricing Policies
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congrats on...
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
U.S. Pressures Germany to Increase Payments for Prescription Drugs Amid Trade Tensions
WASHINGTON — Over a recent breakfast, U.S. officials had a message for the German ambassador: pay more for pharmaceuticals. The meeting, between U.S....
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...